Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | HMGCR | P04035 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | THPO | P40225 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | APEX1 | P27695 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5174067 | 0.97 | ALDH1A1 (0.39) | ALDH1A1TSHRCHRNB2CHRNB4CHRNA4 | |
| Benzene SCHEMBL1002002 | 0.92 | CCR5 (0.37) | ALDH1A1TSHRHMGCRCHRM1TBXA2R | |
| SCHEMBL19169705 | 0.83 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL23518445 | 0.82 | HMGCR (0.33) | TSHRHMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL1515322 | 0.80 | HMGCR (0.32) | TSHRHMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL14159859 | 0.80 | ALDH1A1 (0.39) | ALDH1A1TSHRCHRNB2CHRNB4CHRNA4 | |
| SCHEMBL15247980 | 0.78 | KDM4E (0.31) | HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL19608927 | 0.78 | ALDH1A1 (0.37) | ALDH1A1TSHRCHRNB2CHRNB4CHRNA4 | |
| SCHEMBL24967823 | 0.78 | HMGCR (0.31) | HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL1515304 | 0.78 | ALDH1A1 (0.37) | ALDH1A1TSHRCHRNB2CHRNB4CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3363788-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2018-08-22 | — | — | EP | claimed |
| US-20130165412-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2013-06-27 | — | — | US | claimed |
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2012-08-23 | — | — | US | claimed |
| EP-2470508-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2012-07-04 | — | — | EP | claimed |
| WO-2011025541-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. (US) | 2011-03-03 | — | — | WO | claimed |
| US-5916907-A | Method for preventing or treating low renin hypertension by administering an endothelin antagonist | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-06-29 | — | — | US | claimed |
| US-5780473-A | Substituted biphenyl sulfonamide endothelin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-07-14 | — | — | US | claimed |
| US-20240226107-A1 | UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR | HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230338341-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| US-20230338341-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| US-20230312591-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2023-10-05 | — | — | US | disclosed |
| US-11771695-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-7173036-B2 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTICALS (US) | 2007-02-06 | — | — | US | disclosed |
| EP-1052984-A1 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-11-22 | — | — | EP | disclosed |
| WO-1999039704-A1 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-08-12 | — | — | WO | disclosed |
| US-5916907-A | Method for preventing or treating low renin hypertension by administering an endothelin antagonist | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-06-29 | — | — | US | disclosed |
| US-5780473-A | Substituted biphenyl sulfonamide endothelin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-07-14 | — | — | US | disclosed |
| US-5294708-A | Antidiabetic agents | MCNEILAB, INC. (US) | 1994-03-15 | — | — | US | disclosed |
| US-5268373-A | Containing a benzene ring | MCNEILAB, INC. (US) | 1993-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | ALDH1A1 3623/4885TSHR 1295/4885CHRNB2 139/4885 |
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | EP300, KAT2A, KAT6A | ALDH1A1 2786/4885TSHR 3589/4885CHRNB2 2193/4885 |
| US-20240226107-A1 | UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR | USP1, USP2, USP3 | ALDH1A1 582/4885TSHR 4093/4885CHRNB2 4499/4885 |
| US-20230312591-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | ALDH1A1 2489/4885TSHR 1842/4885CHRNB2 482/4885 |
| US-11771695-B2 | Cannabinoid receptor modulators | CNR2, CNR1, OPRL1 | ALDH1A1 2692/4885TSHR 1154/4885CHRNB2 144/4885 |
| US-20130165412-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | ALDH1A1 3623/4885TSHR 1295/4885CHRNB2 139/4885 |
| US-20230338341-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | ALDH1A1 1382/4885TSHR 745/4885CHRNB2 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.